Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II studyZhi Peng, Lin Shen, Suxia Luo et al.|癌症：英文版|2021Cited by 207
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Lin Xie, Yanqiao Zhang et al.|Nature Medicine|2025Cited by 89
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trialFeng Bi, Weijian Guo, Jian Dong et al.|Journal of Hematology & Oncology|2024Cited by 8
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Lin Xie, Yanqiao Zhang et al.|Nature Medicine|2025Cited by 2